Demographic trends that boosted big gains in prior years haven't gone away.
Impax Laboratories CEO G. Frederick Wilkinson steps down amid a Department of Justice generic price-fixing investigation. J. Kevin Buchi, who joined the board last month, was tapped as interim CEO.
Shares of leading generics fall as more charges are expected.
The India pharma giant also purchases an 85.1% interest in Biosintez for $60 million.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.